Key Takeaway: June 30, 2019 Without Impact of Financing Pro Forma Adjustments Resulting from Financings Post Pro Forma Adjustments Assets: Current $ 9,984,381 $ 1,275,750 $ 11,260,131 Non-current $ 235,352 $ 235,352 Total Assets $ 10,219,733 $ 1,275,750 $
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+97%
120-day peak, hindsight
Typical move
17.7%
average across 7 past catalysts
Cash runway
~68 mo
Minimal dilution risk
Lead asset
REL-1017
Phase 3 · Major Depressive Disorder
Full Press Release Details
June 30, 2019
Without Impact of Financing
Pro Forma Adjustments Resulting from Financings
Post Pro Forma Adjustments
Assets:
Current
$
9,984,381
$
1,275,750
$
11,260,131
Non-current
$
235,352
$
235,352
Total Assets
$
10,219,733
$
1,275,750
$
11,495,483
Liabilities and stockholders' equity:
Current
$
2,606,418
$
-
$
2,606,418
Non-current
$
-
$
-
$
-
Total Liabilities
$
2,606,418
$
-
$
2,606,418
Stockholders' equity
$
7,613,315
$
1,275,750
$
8,889,065
Total liabilites and stockholders' equity
$
10,219,733
$
1,275,750
$
11,495,483
Pro Forma adjustment is to account for the warrant exercise and Private Placement closed in September, 2019